Derfor forventes den metaboliske clearance for vildagliptin ikke at blive påvirket af samtidig administration af præparater, der er CYP 450- hæmmere og/ eller - induktorer.
Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent, and accordingly the metabolic clearance of vildagliptin is not anticipated to be affected by co- medications that are CYP 450 inhibitors and/or inducers.